Long noncoding RNAs (lncRNAs) have been implicated in hypoxia/HIF-1-associated cancer progression through largely unknown mechanisms. Here we identify MIR31HG as a hypoxia-inducible lncRNA and therefore we name it LncHIFCAR (long noncoding HIF-1α co-activating RNA); we describe its oncogenic role as a HIF-1α co-activator that regulates the HIF-1 transcriptional network, crucial for cancer development. Extensive analyses of clinical data indicate LncHIFCAR level is substantially upregulated in oral carcinoma, significantly associated with poor clinical outcomes and representing an independent prognostic predictor. Overexpression of LncHIFCAR induces pseudo-hypoxic gene signature, whereas knockdown of LncHIFCAR impairs the hypoxia-induced HIF-1α transactivation, sphere-forming ability, metabolic shift and metastatic potential in vitro and in vivo. Mechanistically, LncHIFCAR forms a complex with HIF-1α via direct binding and facilitates the recruitment of HIF-1α and p300 cofactor to the target promoters. Our results uncover an lncRNA-mediated mechanism for HIF-1 activation and establish the clinical values of LncHIFCAR in prognosis and potential therapeutic strategy for oral carcinoma.
Hypoxia is a common feature of rapidly growing solid tumours, tightly associated with tumour metastasis and poor prognosis, and a contributor to malignant progression and aggressive phenotype in many cancer types. Hypoxia-inducible factor-1 (HIF-1), a heterodimer consisting of α- and β-subunits, is a key regulator of the cellular response to hypoxia. Under hypoxic conditions, the HIF-1α subunit is stabilized and translocated to the nucleus where it forms a stable HIF-1 complex, specifically bound to the promoter regions of HIF-1 target genes and thereby inducing gene transcription1. Proteins encoded by HIF-1 target genes are involved in multiple aspects of tumourigenesis, including glucose and energy metabolism, proliferation, cancer stem-like properties, angiogenesis, invasion and metastasis1,2. The activation of HIF-1 pathways is associated with an aggressive tumour phenotype and poor clinical outcome in numerous cancer types, including oral cancer3. Oral squamous cell carcinoma (OSCC) represents one of the most common malignancies worldwide with a high mortality rate mainly due to lack of early detection markers, frequent association with metastasis and aggressive phenotype. Thus, there is an urgent need to identify biomarkers and therapeutic targets for this disease.
The recent discovery of long noncoding RNAs (lncRNAs) has gained widespread attention as a new layer of regulation in biological processes. It has been shown that lncRNAs function primarily through their interactions with cellular macromolecules, such as chromatin DNA, proteins and RNAs4,5,6. Accumulating evidence links mutations and dysregulations of lncRNAs to various human diseases ranging from neurodegeneration to cancer7,8,9,10. To date, numerous cancer-associated lncRNAs are reported to modulate tumour growth, invasion and metastasis, and have been implicated as potential alternative biomarkers and therapeutic targets for cancer9,10. Although several hypoxia responsive lncRNAs have been reported to play important roles in HIF-1 pathway regulation and tumorigenesis processes11,12,13, none was shown to modulate HIF-1 transactivation ability through direct interaction with it.
MIR31HG (also known as LOC554202; Accession number: NR_027054) is the host gene of microRNA (miRNA), miR-31, which is mapped to the first intron of MIR31HG14. Accordingly, the transcriptional regulation of miR-31 was shown to follow that of its host gene MIR31HG and both are epigenetically regulated by promoter methylation14. MIR31HG is significantly upregulated in lung15, breast16 and pancreatic cancer17, whereas MIR31HG knockdown inhibited cell growth, invasion16,17 and induced a p16INK4A-dependent senescence phenotype18. By contrast, MIR31HG downregulation is reported in colorectal19 and gastric cancer20. The functional role and the underlying mechanism of MIR31HG in hypoxia-associated cancer progression remain largely elusive.
In a comprehensive survey of lncRNAs regulated by hypoxia, we identify MIR31HG as a species that is significantly upregulated. Here we describe a previously unrecognized role of the mature, spliced form of MIR31HG as a co-activator of HIF-1α that activates the pseudohypoxia signature required for hypoxia-induced metabolic reprogramming, sphere-forming ability and metastatic potential. As this RNA species does not contain miR-31 sequence and functions independently, we refer to it as LncHIFCAR (long noncoding HIF-1α co-activating RNA). We also uncover the upregulation of LncHIFCAR/MIR31HG in oral carcinoma and the clinical relevance of LncHIFCAR as an independent adverse prognostic predictor for the cancer progression. Given its significance in the HIF-1 signalling pathway, LncHIFCAR/MIR31HG represents a novel and potential therapeutic target for the treatment of oral carcinoma.
The expression of lncRNA LncHIFCAR is induced by hypoxia
To identify lncRNAs involved in HIF-1 signalling pathway and hypoxia-associated cancer progression, we initially selected 37 cancer-associated lncRNAs (listed in Supplementary Data 1) according to previous reports8,21 and examined their expression profiles in HeLa cells before and after hypoxia treatment using quantitative real-time PCR (qRT–PCR). Validation of a panel of known hypoxia-inducible protein-coding genes by qRT–PCR confirmed the robustness of our screenings (Supplementary Fig. 1). Compared with non-hypoxic controls, several lncRNAs with a >2-fold alteration in expression were identified under hypoxic conditions (Fig. 1a). Notably, several hypoxia-responsive lncRNAs reported by recent studies, such as H19 (ref. 22) and lncRNA-UCA1 (ref. 23), were also identified in this test. In addition, taking advantage of the hypoxia-mimetic agent cobalt chloride, known to stabilize HIF1α by inactivating prolyl hydroxylases and induce a cellular pseudo-hypoxic state24, we examined the expression of the lncRNAs and identified five of them upregulated by >2-fold after treatment of cobalt chloride in HeLa cells (Fig. 1b). These lncRNAs include four of those induced in physical hypoxia. LncHIFCAR/MIR31HG was the most substantially upregulated lncRNA in response to cobalt chloride treatment and displayed a time- and dose-dependent induction (Supplementary Fig. 2). Similar to the chemically induced pseudo-hypoxic conditions, a time-dependent increase of LncHIFCAR was also observed in physical hypoxic HeLa cells (Fig. 1c), confirming LncHIFCAR as a specific, hypoxia-inducible lncRNA that is possibly involved in HIF-1α signalling pathway.
LncHIFCAR is a prognostic biomarker for OSCC
To evaluate the clinical significance of LncHIFCAR in cancer progression, we first queried the Oncomine database (www.oncomine.com) to systematically assess the relative LncHIFCAR expression in different cancer types (normal versus cancer). Several types of cancer were found to exhibit a significant up-regulation of LncHIFCAR, including OSCC (P=2.2 × 10−17, Student’s t-test; Fig. 1d)25, colon adenocarcinoma, rectal adenocarcinoma, thyroid cancer26,27 and breast cancer28 (Supplementary Fig. 3). Consistent with the published OSCC data set, in a panel of 15 matched pairs of clinical specimens containing OSCC tumours and the surrounding non-cancerous mucosa tissues, LncHIFCAR was substantially upregulated in the tumour samples with a >2-fold overexpression in 8 out of the 15 (53%) samples (Fig. 1e). Notably, as OSCC is the most common type of head and neck SCC (HNSCC), we also surveyed the RNA sequencing data of The Cancer Genome Atlas (TCGA) HNSCC study using cBioPortal platform29,30 and found a significantly upregulated LncHIFCAR expression in HNSCC tumour samples (Supplementary Fig. 4). To assess the clinical significance of LncHIFCAR in OSCC, we next examined the relationship between LncHIFCAR expression level and the clinicopathological characteristics of 42 OSCC samples. High LncHIFCAR expression was significantly associated with age (P=0.037, Fisher’s exact test) and advanced tumour grade (P=0.01, Fisher’s exact test), whereas no significant relationship with any other clinicopathological characteristics was observed (Supplementary Table 1). Kaplan–Meier survival analysis was then performed to compare the outcomes of patients dichotomized by LncHIFCAR expression. Patients with high LncHIFCAR expression level had a significantly worse overall survival (OS, P=0.021, log-rank test; Fig. 1f) and recurrence-free survival (RFS, P=0.004, log-rank test; Fig. 1g) than those with low LncHIFCAR expression. Moreover, similar to the prognostic values of lymph node metastasis (N0 versus N1–3) and tumour differentiation (G1 versus G2+G3), the univariate cox regression analysis indicated high LncHIFCAR expression as another strong prognostic predictor for poor OS (hazard ratio (HR)=2.701, P=0.037) and RFS (HR=3.686, P=0.002, Table 1). To further verify the robustness value of LncHIFCAR expression, multivariate analysis was performed to determine risk assessment related to OS and RFS. Most remarkably, high expression of LncHIFCAR was identified as an independent prognostic factor for RFS (HR=3.5, P=0.012, multivariate analysis; Table 1). Together, our data revealed that LncHIFCAR is overexpressed in OSCC/HNSCC, and that the level of LncHIFCAR could serve as an independent prognostic indicator of clinical outcomes in OSCC patients.
LncHIFCAR contributes to cancer progression
To evaluate the possible role of LncHIFCAR in oral cancer, we first analysed the level of LncHIFCAR in a panel of OSCC cell lines, OECM1, OC-2, HSC-3 and SAS. Compared with OEC-M1 and OC-2 cells established from primary OSCC tumours that exhibit minimal invasion capacity31, the highly invasive HSC-3 and SAS cells expressed higher LncHIFCAR level (Fig. 2a), indicating a possible association of LncHIFCAR with the invasion ability of OSCC cell lines. Similar to HeLa cell, LncHIFCAR expression is also substantially induced in SAS cells upon chemical-induced pseudohypoxia or physical hypoxia in a dose- and time-dependent manner (Supplementary Fig. 5).
Cellular response to hypoxia is implicated in many critical aspects of cancer progression, including invasion, metastasis, stem properties maintenance and metabolism reprogramming. To further characterize the biological significance of LncHIFCAR in oral tumorigenesis, we knocked down this lncRNA with two independent small interfering RNAs (siRNAs). In addition, we used short hairpin RNA (shRNA)-expressing plasmids to generate stable LncHIFCAR knockdown clones (sh-HIFCAR) and vector controls (sh-Ctrl) in SAS cells, and examined the hypoxia-associated phenotypes in these cells. Notably, although miR-31 is located within the first intron of LncHIFCAR and shares the same transcription promoter14, the LncHIFCAR knockdown shRNA/siRNA was designed to target the exon region and thus only specifically downregulated LncHIFCAR but not miR-31, as determined by quantitative PCR (Fig. 2b and Supplementary Fig. 6a). As depicted in Fig. 2c and Supplementary Fig. 6b, the transwell assays showed that LncHIFCAR knockdown resulted in a significantly impaired migration and invasion ability of SAS cells under hypoxia, echoing the positive correlation between LncHIFCAR levels and the invasion ability of different OSCC cell lines (Fig. 2a). Consistent with previous report that knockdown of LncHIFCAR impeded the growth of breast cancer cell16, the LncHIFCAR-knockdown oral cancer cells also grew more slowly than the vector control (Fig. 2d and Supplementary Fig. 6c), whereas LncHIFCAR overexpression promoted the cell growth of SAS and 293T cells (Supplementary Fig. 6d) under normoxic and hypoxic conditions. Notably, the differences in cell proliferation became markedly more profound under hypoxic conditions (2.1-fold, Fig. 2d, right panel) than under normoxic conditions (1.2-fold, Fig. 2d, left panel), revealing a crucial role of LncHIFCAR in hypoxic cell growth. In addition, with normalization to cell number, we detected a significant reduction of hypoxia-induced glucose uptake (Fig. 2e and Supplementary Fig. 6e) and lactate production (Fig. 2f and Supplementary Fig. 6f) in the LncHIFCAR-knockdown SAS cells, suggesting that LncHIFCAR is essential for glycolysis in hypoxia and confers a proliferation advantage to hypoxic oral cancer cells. We then tested anchorage-independent sphere formation and found that, compared to the control cells, LncHIFCAR knockdown cells exhibited significantly weaker tumour sphere-forming ability (Fig. 2g and Supplementary Fig. 6g). Together, these data suggest that LncHIFCAR acts as a critical mediator in hypoxia-associated tumorigenesis including migration, invasion, hypoxic cell growth, metabolic regulation and the sphere-forming ability in OSCC cells.
LncHIFCAR activates HIF-1 transcriptional network
HIF-1, consisting of HIF-1α and HIF-1β subunits, is the primary factor driving cellular response to hypoxia by activating the expression of target genes involved in critical steps of phenotype changes in cancer progression, including angiogenesis (VEGF, vascular endothelial growth factor), mitochondrial function (BNIP3, BCL2/Adenovirus E1B 19 kDa interacting protein 3), metabolism reprogramming (GLUT1/SLC2A1, glucose transporter 1; LDHA, lactate dehydrogenase A; CA9, carbonic anhydrase 9; PDK1,pyruvate dehydrogenase kinase isozyme 1), invasion (LICAM, L1 cell adhesion molecule) and metastasis (LOXL2, lysyl oxidase homologue 2)32,33. Given its role in the hypoxia-associated cancer phenotypes, we next investigated the impact of LncHIFCAR on the expression of HIF-1 target genes. Strikingly, overexpression of LncHIFCAR but not RMRP, another hypoxia-inducible lncRNA, induced the activation of HIF-1 target genes, known as pseudohypoxia, without a significant change of HIF1A messenger RNA in HeLa cells under normoxic condition (Fig. 3a). Furthermore, induction of the pseudohypoxia signature showed a positive correlation with the levels of LncHIFCAR (Fig. 3b) and appeared to be HIF-1α specific, as the expression of non-HIF-1 target RPL13A (ribosomal protein L13a) and HIF-2 target CITED2 (CBP/p300-interacting transactivator 2) remained unchanged upon LncHIFCAR overexpression (Fig. 3b). Reciprocally, knockdown of LncHIFCAR significantly attenuated the activation of HIF-1-specific target genes in chemical-induced pseudo-hypoxic HeLa cells (Fig. 3c and Supplementary Fig. 7a), as well as in the SAS cells under physical hypoxic condition (Fig. 3d and Supplementary Fig. 7b), indicating that LncHIFCAR plays a central role in the activation of HIF-1 target genes.
Remarkably, transcriptional profiling of the tumour spheres suggested that the LncHIFCAR-mediated HIF-1 activation may functionally contribute to the sphere-forming ability in OSCC cells. When we examined the expression of LncHIFCAR and the HIF-1 target genes in HSC-3 and SAS parental and their sphere-forming cells, profound upregulation of LncHIFCAR levels accompanied with HIF-1 target gene induction was detected in the sphere-forming cells (Fig. 3e). Our findings of LncHIFCAR's participation in the anchor-independent sphere formation (Fig. 2g and Supplementary Fig. 6g), combined with LncHIFCAR-dependent HIF-1 target activation (Fig. 3c,d and Supplementary Fig. 7a,b) suggest LncHIFCAR may facilitate cellular adaption to the developing hypoxia at the core of the spheres. Using the immmunohistochemical hypoxia marker pimonidazole, we observed a hypoxic gradient in the spheres (Fig. 3f and Supplementary Fig. 8). Florescence staining with propidium iodide (PI) identifies necrotic cells in these hypoxic core region of spheres (Supplementary Fig. 9). PI counterstaining of spheres with comparable size showed that knockdown of LncHIFCAR induced more necrotic cell death (Supplementary Fig. 10), suggesting that LncHIFCAR knockdown cells were unable to adapt to the developing hypoxia at the core of the spheres. Collectively, these results underscore a crucial role of LncHIFCAR in the activation of HIF-1 target genes, hypoxia adaption and sphere formation that may further contribute to tumour development.
To further validate the clinical relevance of LncHIFCAR with HIF-1 targets expression, we queried RNA sequencing29,30 and mRNA microarray data25,28 in published data sets from a variety of cancer studies. Congruent with our findings, HIF-1 target genes LDHA (Pearson’s correlation r=0.41) and L1CAM (r=0.37) showed a positive correlation with the expression of LncHIFCAR in the TCGA HNSCC provisional cohort29,30 (n=522; Fig. 3g), whereas no significant correlation with the HIF1A mRNA levels were observed (r=0.2). Similarly, the mRNA of other HIF-1 targets such as LOXL2, PGK1, VEGFA and GLUT1 were also significantly elevated in human OSCC25, invasive ductal breast carcinoma28, colon and rectal adenocarcinoma that highly express LncHIFCAR, but not HIF1A mRNA (Table 2). On the other hand, the expression of HIF-2 target CITED2 was not significantly altered in the above-cancer tissues (Table 2), revealing a specific correlation of LncHIFCAR with the HIF-1 transcriptional network.
We next determined whether LncHIFCAR functions through a direct effect on HIF-1 transactivation potency. A HIF-1α reporter plasmid (HRE-FLuc) containing three hypoxia-response elements (HREs) and firefly luciferase coding sequences was used for the promoter-activity assay. Ectopic expression of HIF-1α (3.62-fold) or LncHIFCAR (1.26-fold) alone increased HIF-1 transcriptional activity, whereas co-expression of HIF-1α and LncHIFCAR synergistically enhanced the promoter activity (6.94-fold; Fig. 3h). In a reciprocal experiment, LncHIFCAR-silencing led to a significant reduction in hypoxia-stimulated or ectopic HIF-1α-induced HIF-1 transcriptional activation (Fig. 3i and Supplementary Fig. 11). Taken together, these data suggest that LncHIFCAR augments the transcriptional activity of HIF-1α and serves as a critical regulator of HIF-1 transcriptional network, which enhances the anchorage-independent growth and provides a growth advantage for tumour cells for hypoxia adaptation.
LncHIFCAR acts as a HIF-1α co-activator
The major mechanism of HIF-1 activation in hypoxia is attributed to the stabilization of HIF-1α protein. We found that neither overexpression nor knockdown of LncHIFCAR had a significant impact on the protein level of HIF-1α either under normoxic, chemical-induced pseudo-hypoxic or physical hypoxic conditions (Fig. 4a and Supplementary Fig. 12). In addition, western blotting analysis of nuclear and cytosolic fractions revealed no detectable changes in the hypoxia-induced HIF-1α nuclear accumulation in LncHIFCAR-knockdown cells compared with control cells (Supplementary Fig. 13). Meanwhile, there is no noticeable difference in the subcellular localization of the LncHIFCAR lncRNA in normoxic and hypoxic conditions (Supplementary Fig. 14). These results suggest a mechanism for LncHIFCAR-mediated HIF-1 activation independent of protein stabilization and translocation of HIF-1α.
Under normoxia conditions, the expression of HIF-1α proteins is generally low. We asked whether this low HIF-1α expression is required for LncHIFCAR‐induced pseudohypoxia signature and HIF-1 transactivation as seen in Fig. 3a,b,h. We found that they both were reverted by HIF-1α knockdown (Supplementary Fig. 15), indicating the critical role of HIF-1α in LncHIFCAR-mediated HIF-1 target gene regulation. Therefore, we next examined the physical interaction of LncHIFCAR and HIF-1α. Using nuclear extracts of SAS cells, RNA immunoprecipitation assay showed a robust and specific enrichment of LncHIFCAR co-precipitated within the HIF-1α immunocomplex in cells under hypoxia, whereas no enrichment was detected for other RNA molecules such as GAPDH mRNA, 18S rRNA, a comparable sized lncRNA PCAT1, and hypoxia-inducible RMRP and MALAT1 lncRNAs (Fig. 4b). The physical interaction between LncHIFCAR and HIF-1α was confirmed by RNA pull-down assay using hypoxic cell nuclear extracts incubating with in vitro transcribed biotinylated LncHIFCAR (Fig. 4c). With purified recombinant HIF-1α protein in the in vitro binding assay, we further validated that LncHIFCAR associated with HIF-1α through direct binding (Fig. 4d).
To delineate the structural determinants for the association between LncHIFCAR and HIF-1α, RNA pull-down assays were performed with a series of LncHIFCAR truncated fragments. Both the 5′-terminal (nucleotides 1–500) and 3′-terminal (nucleotides 1,500–2,166) regions were found to be associated with HIF-1α (Fig. 4d). As expected, the HIF-1α association was abolished when using a truncated LncHIFCAR (nucleotides 501–1,500) that lacked the two binding regions (Fig. 4e), confirming that the critical HIF-1α-interaction regions in LncHIFCAR reside at the 5′-terminal (nucleotides 1–500) and 3′-terminal (nucleotides 1,500–2,166) sections. To further explore functional relevance of the LncHIFCAR/HIF-1α interaction, the full-length and deletion mutant LncHIFCAR (501–1,500) were overexpressed in SAS cells. As shown in Fig. 4f and Supplementary Fig. 16, relative to full-length LncHIFCAR, the ability of the HIF‐1α binding-deficient mutant LncHIFCAR (501–1,500) to induce HIF-1 target genes and HIF-1 responsive luciferase reporter was severely impaired. This result suggests that the HIF-1α-binding regions functionally contribute to the LncHIFCAR-mediated HIF-1 target induction. We next mapped HIF‐1α domain required for LncHIFCAR binding by generating HIF‐1α bHLH (basic helix–loop–helix; amino acids 1–80), PAS-A (Per-ARNT-Sim-A; amino acids 81–200), PAS-B (Per-ARNT-Sim-B; amino acids 201–329) and TAD (transactivation domain; amino acids 191–445) deletion mutants (Fig. 4g, bottom panel). In vitro pull-down assays revealed that LncHIFCAR strongly bound to the PAS-B domain of HIF‐1α (Fig. 4g and Supplementary Fig. 17). As this domain is responsible for functional dimerization, we then conducted immunoprecipitation of HIF‐1α with hypoxic cell lysate to investigate the effect of LncHIFCAR on HIF1 complex formation. Knockdown of LncHIFCAR reduced the interaction between HIF‐1α and both HIF‐1β and p300 (Fig. 4h), indicating that LncHIFCAR could facilitate the recruitment of HIF-1 complex. Collectively, the data presented in Figs 3 and 4 indicates that LncHIFCAR functions as a transcriptional co-activator of HIF-1α. Given that the HIF-1α level in many tumour cells can remain elevated under normoxic conditions34,35, LncHIFCAR may induce pseudohypoxia signature by promoting HIF-1 complex formation under normoxia.
LncHIFCAR enhances HIF-1 complex binding to the target loci
To verify whether LncHIFCAR directly acts on the target chromatins, we analysed the loci of LncHIFCAR-dependent HIF-1 target genes as identified in Fig. 3d by employing chromatin isolation by RNA purification (ChIRP). A set of probes complementary to LncHIFCAR was used to pull down the endogenous LncHIFCAR from normoxic or hypoxic SAS cells and the promoter regions of known HIF-1α-binding sites were amplified and quantified by quantitative PCR (qPCR). In concordance with the notion that LncHIFCAR functions as a HIF-1α co-activator, the ChIRP analysis showed that LncHIFCAR is recruited to a subset of the HIF-1 target promoters in hypoxic cells, suggesting overlapping chromatin occupancy of LncHIFCAR and HIF-1α under hypoxia (Fig. 5a). As hypoxia-induced target activation is mediated by HIF-1 transcriptional complex composed of HIF-1 heterodimer and the transcription cofactor p300/CBP2,36, we next examined whether the chromatin binding of LncHIFCAR is involved in the recruitment of HIF-1α and the cofactor upon hypoxia. Significantly, the chromatin immunoprecipitation (ChIP) assays using anti-HIF-1α and anti-p300 antibodies showed that these transcriptional factors were enriched on the target promoters in hypoxic cells, whereas knockdown of LncHIFCAR significantly reduced this chromatin enrichment (Fig. 5b,c). These results suggest that under hypoxia, LncHIFCAR forms a complex with HIF-1α and enhances the chromatin recruitment of HIF-1α and p300 cofactor, thereby promoting the transcriptional reprogramming essential in multiple oncogenic pathways.
LncHIFCAR promotes metastatic cascade
With our evidence of LncHIFCAR in HIF-1 activation and hypoxia-associated cancer phenotypes, the biological significance of LncHIFCAR in oral cancer progression in vivo was examined using mouse xenograft model. The vector control and LncHIFCAR knockdown SAS cells were genetically modified to express firefly luciferase, and subsequently injected intravenously into nude mice (Day 0). Following tail vein inoculation, the bioluminescence intensity of the lung region was measured weekly up to 6 weeks. Although the vector control cells exhibited strong colonization to the lung with a timely progression, LncHIFCAR-knockdown cells showed a drastically reduced ability to colonize in lung (Fig. 6a–c and Supplementary Fig. 18). Verified by histology, a significantly increased incidence of pulmonary metastasis was observed in the mice bearing vector control cells, whereas only rare tumour foci were found in the lungs of mice carrying LncHIFCAR knockdown cells (Fig. 6d–f). Notably, the difference in tumour foci size and occurrence cannot be fully accounted for by cell proliferation rate caused by LncHIFCAR modulation under normoxia. As judged from the time-lapsed image of Supplementary Fig. 18, control vector-expressing cells colonized to the lung 14 days after tail vein injection. By contrast, the LncHIFCAR knockdown xenografts showed significant less lung colonization at the same time point when no apparent change of the injected cell density was observed compared with the control group (Day 14, Fig. 6a,b and Supplementary Fig. 18). Given the critical role of hypoxic signalling in the formation of a premetastatic niche essential for tumour colonization at the distant site1,2, we propose that LncHIFCAR-mediated difference in colonization ability is a combined effect of enhanced HIF-1 signalling activation and increased hypoxic tumour cell growth advantage conferred by this lncRNA. Altogether, these results suggest that LncHIFCAR enhanced the metastatic spread of SAS oral cancer cells in vivo, further substantiating its oncogenic potential in OSCC progression.
Hypoxia exists in majority of solid tumour and contributes to local and systemic cancer progression, therapeutic response and poor outcome. Given the pivotal roles of lncRNA in gene expression, the critical involvements of lncRNA in hypoxia-associated malignant progression have been recognized and vigorously studied. Recent reports have identified several hypoxia-responsive lncRNAs. Among them, lncRNA-PRINS (ref. 37), lncRNA-EFNA3 (ref. 38), lncRNA-UCA1 (ref. 23), lncRNA-AK058003 (ref. 39), lncRNA-AK123072 (ref. 40), lncRNA-NUTF2P3-001 (ref. 41), linc-p21 (ref. 42), MALAT1 (ref. 43), HOTAIR (ref. 44), NEAT1 (ref. 43), linc-ROR (ref. 45), HINCUTs (ref. 46), H19 (ref. 22), WT1 (ref. 47) and HIF1A-AS2 (aHIF) (ref. 48) are upregulated, whereas lncRNA-LET (ref. 49) and ENST00000480739 (ref. 50) are downregulated in response to hypoxia. Interestingly, lncRNA-SARCC could differentially respond to hypoxia in a VHL-dependent manner51. Most of these hypoxia-regulated lncRNAs are functionally characterized and have profound impact on tumorigenesis in a spectrum of cancer types. However, only few have been fully characterized with respect to the detailed mechanisms of action, with the roles of the majority others remain largely unknown. At epigenetic level, WT1 modulates histone modification47, whereas AK058003 regulates DNA methylation39. In addition, lncRNAs may regulate HIF-1 signalling by acting as a miRNA sponge (lncRNA-NUTF2P3-001 versus miR-3923 (ref. 41) and linc-ROR versus miR-145 (ref. 45)) or by functioning as antisense lncRNAs (aHIF1α48 and HIF2PUT52). Moreover, through lncRNA–protein interaction, hypoxia-responsive lncRNAs, such as lncRNA-LET49, lincRNA-p21 (ref. 42) and LINK-A53, modulate HIF-1 signalling via their effects on the expression, degradation and phosphorylation of HIF-1α, respectively. Our present study identified LncHIFCAR as another hypoxia-inducible lncRNA and described a distinct mechanism, whereby LncHIFCAR modulates HIF-1 transcriptional activation independent of the stabilization or cellular translocation of HIF-1α. We found that LncHIFCAR is highly elevated in oral cancer, and that the LncHIFCAR-dependent activation of HIF-1 modulates target genes expression and thereby confers metabolic reprogramming and a hypoxic proliferation advantage required in several tumour progression steps including sphere-forming ability and metastatic colonization capability (Fig. 6g).
Mechanistically, we showed that LncHIFCAR directly interacts with HIF-1α and associates with the chromatin loci of HIF-1 target promoters. Such chromatin complex formation enhanced the recruitment of co-activator p300 and via which facilitated the activation of HIF-1 transcriptional network. This evidence along with the finding that co-expressing LncHIFCAR and HIF-1α synergistically enhanced the HIF-1 reporter activity, strongly suggests that LncHIFCAR functions as a co-activator of HIF-1α. Of note, LncHIFCAR/MIR31HG is also reported to associate with the promoter of its own gene18, we thus speculate a LncHIFCAR-dependent hypoxia response through a positive feedback mechanism: the hypoxia-induced LncHIFCAR expression and HIF-1α stabilization presumably result in an increased abundance of the LncHIFCAR/HIFα complex, which works in concert to further enhance the transcription of LncHIFCAR and the activation of HIF-1. Further study will help elucidate the possible self-regulation of the LncHIFCAR-HIFα axis in hypoxia. Interestingly, our data revealed that, in addition to hypoxia, LncHIFCAR can also enhance the expression of HIF-1 target genes under normoxic condition. Considering that in certain circumstances, the level of HIF-1α in tumour cells can remain elevated under normoxic conditions34, it is possible that LncHIFCAR also plays an important role in regulating the normoxic HIF-1 signalling pathway with functional implications in tumour progression.
Overexpression of LncHIFCAR has been previously reported in lung15, breast16 and pancreatic17 cancer tissues, whereas downregulation of LncHIFCAR was found in colorectal19 and gastric20 cancer. A recent report suggests that LncHIFCAR/MIR31HG favour melanoma cancer development by facilitating the binding of Polycomb-group proteins to p16INK4A locus, to suppress its expression18, whereas another study showed that LncHIFCAR acts as an endogenous ‘sponge’ competing for miR-193b binding in the cytoplasm and regulate the miRNA targets17. Together, given its role as transcriptional co-activator as reported here, it appears that LncHIFCAR possesses both nuclear and cytoplasmic functions, and probably affects tumour progression through mechanisms at least in part, depending on its subcellular localization. In addition, through association with different transcription regulator, LncHIFCAR can act either as a co-activator (through interaction with HIF-1α) or co-repressor (by interacting with Polycomb-group proteins). Another lncRNA Evf2 (also known as Dlx6os1) was found to have dual roles in gene regulation in a similar way, depending on whether it recruits the transcription activator DLX2 or the transcription repressor MeCP2 (methyl-CpG binding-protein 2)54,55. These findings surely added another level of complexity to lncRNA-mediated gene regulation. It has been reported that repetitive sequence elements in lncRNAs contribute to RNA-chromatin interactions56. Although LncHIFCAR harbours repetitive elements, no obvious sequence on LncHIFCAR was found complementary to the target loci. At this point, it is still unclear whether the association of LncHIFCAR with target loci is via direct binding or mediated by additional factors. Given that several epigenetic and chromatin modifiers are required for HIF-1 activation under hypoxia57,58, it is possible that the chromatin association of LncHIFCAR promotes epigenetic modification or vice versa. Further investigation will be required to understand how chromatin-associated LncHIFCAR promotes and stabilizes HIF-1 enrichment on the target chromatin.
One of the unmet clinical needs in managing oral cancer patients is the identification of reliable biomarkers for early detection, which is essential for timely treatment before reaching to advanced stage. However, most of protein biomarkers identified for the detection of OSCC are not clinically accessible nor harbor sufficient sensitivity for early detection. Using lncRNA as biomarker for cancer diagnosis and prognosis however has been shown to hold several advantages in light of its sensitivity, specificity, stability and easy accessibility10. With the following evidence, we uncovered a remarkable value of LncHIFCAR for oral cancer prognosis. First, high LncHIFCAR strongly associates with poor OS and RFS of OSCC patients. Second, LncHIFCAR expression strongly correlates with poorly differentiated OSCC, which is known to display early metastasis, high relapse rate and predicts poor outcomes in the patients59,60. Finally, the multivariate analysis identified high LncHIFCAR as an independent risk factor for recurrence-free patient survival. Notably, in multiple microarray and RNA-sequencing data sets where LncHIFCAR and HIF-1 target genes are upregulated in the cancer specimens, the levels of HIF1A mRNA are not significantly altered. This result echoes the controversial views of using HIF1α protein level as a prognostic marker for OSCC3. By contrast, LncHIFCAR is potentially useful to serve as a biomarker to reflect the activation status of HIF-1 signalling in OSCC. Moreover, the roles of LncHIFCAR associating with clinical outcomes are supported by our in vitro and in vivo experiments that demonstrate the invasion- and metastasis-promoting effects of LncHIFCAR. Metastasis is a complex multistep process involving early invasion, intravasation, extravasation and colonization of cancer cells. Consistent with the findings in breast16 and pancreatic17 cancers, we showed that LncHIFCAR knockdown significantly impaired the invasive ability of cultured OSCC cells and strongly compromised the distant colonization of OSCC cells in xenograft models, reinforcing the pleiotropic roles of LncHIFCAR in metastasis cascade. Collectively, we defined a functional link of LncHIFCAR to poorly differentiated tumours with metastatic potential in OSCC and uncovered a potential clinical use for LncHIFCAR as a prognostic marker that may help the disease management.
Many HIF-1 target genes control biological processes essential for cancer progression. For decades, HIF-1 and its downstream effectors such as LDHA, GLUT1 and PDK1, which mediates tumour metabolic adaptation, have been long recognized as potential targets for cancer drug due to their profound impacts in cancer progression61,62,63,64,65,66. However, the complexity of the HIF-1α signalling network and the requirements of targeting protein–protein interactions have made the design of HIF-1α inhibitors very challenging. Recently, targeting lncRNA has been increasingly considered as a promising therapeutic strategy for cancer treatment10. Because of the high expression level and the roles in HIF-1 activation in OSCC, LncHIFCAR holds a great potential to be developed as a specific target for OSCC therapy. To our knowledge, the present work presents the first evidence showing that an lncRNA could modulate hypoxia signalling pathways by acting as a HIF-1α co-activator. The roles of LncHIFCAR in HIF-1α co-activation and the translational relevance of LncHIFCAR in OSCC not only provide new insight into HIF-1 activation but also reveal a potential utility of LncHIFCAR in prognosis and therapeutic strategy for OSCC.
Cell lines HeLa and HEK293T (293T) were obtained from ATCC and cultured in DMEM supplemented with 10% (v/v) fetal bovine serum (FBS) (Gibco/Invitrogen). SAS cell line was obtained from JCRB cell bank and maintained in 1:1 mixture of DMEM and Ham’s F12 medium (Gibco/Invitrogen) with 10% FBS. The oral cancer cell lines OC-2, OEC-M1 and HSC-3 were obtained and maintained as described previously31. Cell lines were not authenticated, but regularly tested for mycoplasma contamination using Venor GeM Detection Kit (Minerva Biolabs). None of the cell line stock used in this study is found in the database of commonly misidentified cell lines listed by ICLAC. Transfection was performed using Lipofectamine 2000 (Invitrogen) or Fugene 6 (Roche Applied Science) as recommended by the manufacturer. To generate stable LncHIFCAR-knockdown SAS cell lines, SAS cells transduced with LncHIFCAR shRNA (sh-HIFCAR) or empty vector (sh-Ctrl) lentiviral particles were selected by Zeocin for 3 weeks. To generate luciferase-expressing and LncHIFCAR-knockdown SAS cell lines for xenograft study, the SAS stable clones (sh-Ctrl 1 and sh-HIFCAR 6) described above were transduced with a lentiviral vector containing firefly luciferase complementary DNA, which was constructed using the ViralPower Lentiviral Gateway Expression System from Invitrogen67, and selected by puromycin for 3 weeks. For hypoxia treatment, physical hypoxic conditions (1% oxygen) were generated by Forma Series II 3130 incubators (Thermo Scientific). Alternatively, to generate chemical-induced pseudo-hypoxic state, cells were treated with hypoxia-mimetic chemical cobalt chloride (Sigma-Aldrich) as indicated.
Total cellular RNA was isolated using Trizol (Invitrogen) reagent and cDNA was generated using SuperScript II first-strand synthesis system (Invitrogen). Real-time qPCR analysis was performed on the Bio-Rad iQ5 Real-Time PCR detection system (Bio-Rad) with Maxima SYBR Green qPCR Master Mix (Fermentas) or on the Rotor-Gene Q instrument (Qiagen) with QuantiFast SYBR Green PCR Kit (Qiagen). All expression levels, unless otherwise specified, were normalized against the GAPDH mRNA level. The primer sequences are listed in Supplementary Data 2. Real-time qPCR for miR-31 was performed using miScript PCR Starter Kit and hsa-miR-31 miScript Primer Assay according to manufacturer’s instructions (Qiagen).
Molecular cloning and siRNA transfection
To generate sense and anti-sense biotin-labelled LncHIFCAR transcripts, full-length LncHIFCAR cDNA was amplified from HeLa nuclear RNA and cloned into pCR2.1-TOPO (Invitrogen) by TA cloning. For in vitro transcription of biotin-labelled LncHIFCAR RNA deletion variants, the corresponding LncHIFCAR fragments were amplified and cloned into pGemT-Easy (Promega) by TA cloning. For ectopic overexpression of full-length RMRP, LncHIFCAR and LncHIFCAR (501–1,500) in human cell lines, the PCR-generated DNA fragments containing the indicated regions were inserted into pCR2.1-TOPO by TA cloning, followed by sub-cloning into the EcoRI site of pSL-MS2 vector. To knock down LncHIFCAR expression, DNA encoding shRNA specifically targeting LncHIFCAR at sequence 5′-GCTGCTGATGACGTAAAGT-3′ was cloned into pLenti4 vector. For siRNA-mediated knockdown of LncHIFCAR, two different siRNA oligonucleotides were synthesized and purified by by Genepharma (Suzhou, Jiangsu, China). siRNAs were transfected at a final concentration of 20 nM using Lipofectamine RNAiMAX Reagent (Invitrogen) following the manufacturer’s protocol. The sequences of siRNAs are listed in Supplementary Table 2. The HIF-1α-expressing plasmid HA-HIF-1α-pcDNA3, as well as the reporter plasmid HRE-luciferase (HRE-FLuc) containing HREs fused with a firefly luciferase, were purchased from Addgene. The pRL-SV40 luciferase constitutive reporter plasmid were purchased from Promega. To express and purify GST-HIF-1α, the PCR-amplified HIF-1α fragments from HA-HIF-1α-pcDNA3 was inserted into pGemT-Easy by TA cloning, followed by sub-cloning into the NotI site of pGEX-6p-1 plasmid (GE Healthcare). To purify GST-HIF-1α deletion variants, the corresponding amplified HIF-1α fragments were cloned into the BamHI/NotI sites of pGEX-6p-1.The integrity of each construct was verified by DNA sequencing and the sequences of specific primers designed for cloning as described above are listed in Supplementary Table 3. The pLKO.1-puro plasmid-based shRNAs, including TRCN0000003808 (HIF1A-sh1) and TRCN0000003809 (HIF1A-sh2), were obtained from the National RNAi Core Facility, Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taiwan.
cBioPortal and Oncomine database analysis
LncHIFCAR expression was analysed using the Oncomine (www.oncomine.org) and cBioPortal (www.cbioportal.org) platforms. For the tumour versus normal analysis of LncHIFCAR (LOC554202) on Oncomine, the following data sets were used: Peng Head-Neck dataset (GEO: GSE25099)25, Vasko Thyroid data set (GSE6004)27, He Thyroid data set (GSE3467)26, Zhao Breast data set (GSE3971)28 and TCGA colorectal data set (TCGA Research Network; http://cancergenome.nih.gov/). The P-value <0.05 was considered statistically significant. For LncHIFCAR/MIR31HG expression analysis and co-expression network discovery, the TCGA HNSCC cohort (TCGA, Provisional)29,30 was analysed on cBioPortal using the default options according to the instructions on the website. Pearson’s and Spearman’s correlations of the expression levels of 20,532 genes in 522 HNSCC cases were accessed and computed by RNA-Seq V2 RSEM data set. By default, only gene pairs with values >0.3 or <−0.3 in both measures are considered statistically significant and shown. Total 248 significantly co-expressed genes were listed, including L1CAM and LDHA.
Cell migration and invasion assay
A total of 3 × 104 cells were suspended in 100 μl of DMEM without FBS and seeded into the top chamber of 24-well plate-sized transwell inserts (BD Falcon, 353097) with a membrane of 8 μm pore size. The medium containing 10% FBS was placed into the lower chamber as a chemoattractant. After incubation for 24 h, the cells that did not migrate through the pores were manually removed with a cotton swab. Cells presented at the bottom of the membrane were fixed and stained with crystal violet and then counted and imaged under microscope. Cell numbers were calculated in eight random fields for each chamber and the average value was calculated. Each experiment was conducted in triplicate. Matrigel invasion assays were performed using Matrigel-coated transwell inserts with the procedure as described above.
Single-cell suspensions of SAS cells were plated (1,000 cells per well) into six-well Ultra Low Attachment plates (Corning) in serum-free DMEM/F12 culture media (Gibco/Invitrogen) supplemented with 2% B27 (Invitrogen), 20 ng ml−1 basic fibroblast growth factor (Invitrogen) and epidermal growth factor (20 ng ml−1, Millipore). The cells were grown in a humidified atmosphere of 95% air and 5% CO2 for 15 days. Upon harvest, the spheres were counted (diameter >100 μm) with inverted phase-contrast microscopy, followed by collection for RNA extraction. For pimonidazole staining, tumour spheres grown in normoxic suspension culture were allowed to attach to 0.1% gelatin-coated cover slips for 12 h. Pimonidazole (Hypoxyprobe-1 Kit, Hypoxyprobe, Burlington, USA) was applied to the spheres for 1 h under normoxia. Intracellular pimonidazole complexes indicative of hypoxic conditions were detected by immunofluorescence microscopy using an anti-pimonidazole monoclonal antibody (1:200, Hypoxyprobe-1 Kit). Cell nuclei were counterstained by Hoechst staining, whereas necrotic cells were labelled with PI fluorescence staining. For quantification of necrotic spheres, suspended tumour spheres were collected by centrifugation for the subsequent PI fluorescence staining.
Luciferase reporter assay
The HIF-1α-responsive luciferase construct (pHRE-FLuc) containing HREs fused with a firefly luciferase was purchased from Addgen. For HRE luciferase assays, cells were seeded to 24-well plates at a density of 1 × 105 per well. After overnight incubation, cells were transiently co-transfected with the pHRE-FLuc reporter plasmid, empty vector, LncHIFCAR-expressing constructs or shRNA vector-targeting LncHIFCAR, as well as an internal control construct pRL-SV40 Renilla luciferase plasmid (Promega). Twenty-four hours post transfection, the media was replaced and the cells were exposed to 20% or 1% O2 for 24 h. At 48 h post transfection, cells were lysed with passive lysis buffer and assayed for firefly and Renilla luciferase activities using Varioskan Flash microplate luminometer (Thermo) with the Dual-Luciferase Assay System (Promega). All the luciferase activity were normalized against the Renilla values and expressed as the relative fold of control group.
Glucose uptake and lactate production assay
The intracellular glucose and extracellular lactate were measured with the fluorescence-based glucose assay and lactate assay kits (BioVision) according to the manufacturer’s instructions, respectively. Vector control and LncHIFCAR-knockdown SAS clones were cultured for 24 h following subsequent treatment of normoxia or hypoxia for 16 h. Intracellular glucose levels and lactate levels in the culture media were measured and presented as folds relative to the level of control cells in normoxia. All measurement were normalized by cell number.
Nuclear and cytoplasmic fractionation
Subcellular fractionation of protein extracts from HeLa cells was performed using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific) following the manufacturer’s protocol. Nuclear/cytoplasmic fractionation of RNA was conducted with Nuclei EZ Lysis Buffer (Sigma), according to the manufacturer’s protocol.
Biotinylated RNA pull-down assay
The biotinylated RNA pull-down assay was performed as described previously68,69. Briefly, biotin-labelled RNAs was in vitro transcribed with AmpliScribe T7-Flash Biotin-RNA Transcription Kit (Epicentre), treated with RNase-free DNase I and purified with an RNeasy Mini Kit (Qiagen). The lambda transcript was generated with the control plasmid provided by the Transcription Kit. To form the proper secondary structure, biotinylated RNA supplied with RNA structure buffer (10 mM Tris pH 7, 0.1 M KCl and 10 mM MgCl2) was heated to 90 °C for 2 min, incubated on ice for 2 min and then shifted to room temperature (RT) for 20 min. The RNA was then mixed with hypoxic HeLa nuclear extract or purified proteins and incubated at RT for 1 h, followed by incubating with Streptavidin Mag Sepharose (GE Healthcare) at RT for 1 h. After subsequent washes, the pull-down complexes were analysed by standard western blot technique.
Antibodies and western blot analysis
Cells were harvested, rinsed with PBS and lysed in lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.4, 1 mM EDTA,1 mM MgCl2, 0.5% NP-40, 1 mM Na3VO4, 1 mM NaF, protease inhibitors cocktail). Cell lysates were separated on SDS–polyacrylamide gel, transferred to a polyvinylidene difluoride membrane (Bio-Rad Laboratories) and immunoblotted using the following primary antibodies. Rabbit anti-HIF-1α (1:1,000, GTX127309), anti-GST (1:5,000, GTX110736), anti-lamin B2 (1:5,000, GTX109894) and anti-tubulin (1:5,000, GTX112141) antibodies, as well as mouse monoclonal anti-HIF-1α antibody (1:1,000, GTX628480), were purchased from GeneTex. Mouse monoclonal antibodies recognizing β-actin (1:5,000, A2228) were purchased from Sigma. Mouse monoclonal HIF-1β antibody [2B10] (1:2,000, ab2771) were purchased from Abcam. Uncropped scans of the blots and gels are shown in Supplementary Fig. 19 in the Supplementary Information section.
Purification of GST-HIF-1α
Escherichia coli host BL21(DE3) harbouring the expression vector pGEX-6p-1-HIF-1α was cultured in Luria–Bertani medium with ampicillin (50 μg ml−1) and induced by 0.3 mM IPTG (isopropyl-β-D-thiogalactopyranoside) at 30 °C for 16 h. Affinity purification of the recombinant protein was carried out with Pierce Glutathione Superflow Agarose (Pierce) following the manufacturer’s instructions.
RNA immunoprecipitation was performed as described previously68,69 with the following modifications. Briefly, 2 × 107 of SAS cells treated with normoxia or hypoxia for 16 h were crosslinked with 0.3% formaldehyde in medium for 10 min at 37 °C, followed by neutralization with 125 mM glycine incubated at RT for 5 min. After two times wash with cold PBS, the cell pellets were lysed in RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% NP-40 and 0.5% sodium deoxycholate, 0.5 mM dithiothreitol, RNase inhibitor and protease inhibitor cocktail), followed by sonication on ice and subsequent DNase treatment for 30 min. Immunoprecipitation were performed by incubating protein A/G precleared nuclear lysates with α-HIF-1α antibody (1:100, NB100-105, Novus Biologicals) or equivalent mouse IgG (GTX35009, GeneTex) at 4 °C overnight. The RNA/antibody complex was then precipitated by incubation with protein A/G agarose beads. After subsequent wash following the standard protocol, the RNA samples were extracted with Trizol reagent (Invitrogen) and detected by qRT–PCR.
Vector control or LncHIFCAR knockdown SAS cells under hypoxic conditions for 24 h were collected by centrifugation. The cell pellet was then resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 180 mM NaCl, 1% NP-40, protease and phosphatase inhibitor cocktail) and passed through a 21-gauge syringe several times. Immunoprecipitations were performed by incubating 1 mg protein A/G precleared cell lysates with 5 μg α-HIF-1α antibody (NB100-105, Novus Biologicals) or equivalent mouse IgG (GTX35009, GeneTex) at 4 °C for 3 h. After subsequent wash, the immunoprecipated protein complex on the beads were analysed by western blotting.
In vitro RNA-binding assay
In vitro-synthesized LncHIFCAR RNA supplied with RNA structure buffer (10 mM Tris pH 7, 0.1 M KCl and 10 mM MgCl2) was heated to 90 °C for 2 min, incubated on ice for 2 min and then shifted to RT for 20 min to form the proper secondary structure. GST fusion proteins on glutathione-Sepharose beads (∼10 μl) were incubated with 2 μg in vitro synthesized LncHIFCAR RNA in 50 μl of RNA-binding buffer (50 mM Tris-HCl, pH 7.4, 100 mM KCl, 2 mM MgCl2, 0.1% NP-40. 1 mM dithiothreitol and ribonuclease inhibitor) for 30 min at 4 °C. The beads were washed with RNA-binding buffer three times to remove unbound RNAs. The RNA samples retained on the beads were extracted with Trizol reagent (Invitrogen) and detected by qRT–PCR. The relative retention as to the input RNA level was calculated.
ChIP assays were performed mainly following the ChIP protocol from the University of California Davis Genome Center (http://farnham.genomecenter.ucdavis.edu). Briefly, vector control or LncHIFCAR knockdown SAS cell lines (2 × 107cells per assay) treated with normoxia or hypoxia were cross-linked with 1% formaldehyde at 37 °C for 15 min and subsequently quenched in 125 mM glycine for 5 min. The cross-linked chromatin was sonicated to generate DNA fragments averaging 200–500 bp in length. Chromatin fragments were immunoprecipitated with antibodies against HIF-1α (1:100, NB100-105, Novus Biologicals), p300 (1:100, 05-257, Millipore) or equivalent mouse IgG (GTX35009, GeneTex). The precipitated DNA were purified using the QIAquick PCR Purification Kit (Qiagen) and analysed by quantitative real-time PCR using the primers listed in Supplementary Data 2.
Chromatin isolation by RNA purification
ChIRP was performed using SAS cells adapting the protocols described previously69,70 with minor modifications. Briefly, 20-mer antisense DNA probes targeting LncHIFCAR RNA, as well as the negative control lacZ RNA, were designed using the online probe designer at singlemoleculefish.com (http://www.singlemoleculefish.com/designer.html) as listed in Supplementary Table 4. SAS cells treated with normoxia or hypoxia for 4 h were crosslinked with 1% glutaldehyde for 10 min at RT with gentle shaking. Crosslinking was stopped with 125 mM glycine for 5 min. The cross-linked chromatin was incubated with the biotinylated DNA probes, subjected to streptavidin magnetic beads capturing and subsequent wash/elution steps essentially performed as described70. The eluted chromatin and RNA fragments were analysed by qPCR using the primers listed in Supplementary Data 2.
Oral cancer SAS cell lines (sh-Ctrl#1 and sh-HIFCAR#6) used for metastasis model were all labelled with firefly luciferase as described above. In brief, 5 × 105 SAS cells (sh-Ctrl#1 and sh-HIFCAR#6, respectively) suspended in 0.5 ml of Matrigel (BD Bioscience) were injected into the tail veins of 6- to 8-week-old female athymic nude mice (nu/nu). Subsequently, the mice were monitored for metastases using the IVIS Lumina LT series III system (PerkinElmer) after intraperitoneal injection of luciferin once a week for 6 weeks after tail vein xenografting. Then, the lungs of the nude mice were excised post mortem for histology examination and haematoxylin–eosin staining. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. The animal studies were approved by National Health Research Institutes Institutional Animal Care and Use Committee (approval number: NHRI-IACUC-102078) and carried out under the institutional guidelines with animal welfare standards.
Patients and clinical samples
The research design, study protocols and information security were approved by the Institutional Review Board of Chi-Mei Medical Center (approval number: 10312-L07). Thereby, snap-frozen primary OSCC tissues and paired non-cancerous mucosa tissues stored in liquid nitrogen were withdrawn from Chi-Mei Medical Center Tissue BioBank. Written informed consents were obtained from all participants. The clinicopathological data for the samples were presented in Supplementary Table 1.
All data were expressed as mean±s.d. of three or more independent experiments. Sample sizes were selected based on experience from our previous publications. Samples were excluded only in the case where a technical error occurred during sample preparation or analysis. Statistical analyses were performed with SPSS software version 19.0 (Armonk). Differences between individual groups were analysed by two-tailed Student’s t-test. The survival curves were calculated using the Kaplan–Meier method and the differences were assessed by a log-rank test. Statistical analyses of clinicopathological data were performed using Fisher’s exact test. Univariate and multivariate Cox proportional hazards regression models were performed to identify the independent factors with a significant impact on patient survival. The HRs and 95% confidence intervals of the prognostic factors were calculated. The results were considered significant if P<0.05.
The TCGA and Oncomine data referenced during the study are available in a public repository from the cBioPortal for Cancer Genomics, TCGA (http://www.cbioportal.org/) and the Oncomine (www.oncomine.org) websites. For the tumour versus normal analysis of LncHIFCAR on Oncomine (search term: LOC554202), the following datasets were used: Peng Head-Neck dataset (Gene Expression Omnibus: GSE25099)25, Vasko Thyroid dataset (GSE6004)27, He Thyroid dataset (GSE3467)26, Zhao Breast dataset (GSE3971)28 and TCGA colorectal data set (TCGA Research Network; http://cancergenome.nih.gov/). For LncHIFCAR expression analysis and co-expression network discovery, the TCGA HNSCC cohort (TCGA, Provisional) was analysed on cBioPortal platform29,30 (search term: MIR31HG). The authors declare that the data supporting the findings of this study are included within the article and its Supplementary Information files, or are available from the authors upon reasonable request.
How to cite this article: Shih, J.-W. et al. Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1α co-activator driving oral cancer progression. Nat. Commun. 8, 15874 doi: 10.1038/ncomms15874 (2017).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Keith, B. & Simon, M. C. Hypoxia-inducible factors, stem cells, and cancer. Cell 129, 465–472 (2007).
Semenza, G. L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. 9, 47–71 (2014).
Po, D. E. L., Jorge, C. C., Oliveira, D. T. & Pereira, M. C. Hypoxic condition and prognosis in oral squamous cell carcinoma. Anticancer Res. 34, 605–612 (2014).
Wang, K. C. & Chang, H. Y. Molecular mechanisms of long noncoding RNAs. Mol. Cell 43, 904–914 (2011).
Bohmdorfer, G. & Wierzbicki, A. T. Control of chromatin structure by long noncoding RNA. Trends Cell Biol. 25, 623–632 (2015).
Bonasio, R. & Shiekhattar, R. Regulation of transcription by long noncoding RNAs. Annu. Rev. Genet. 48, 433–455 (2014).
Wapinski, O. & Chang, H. Y. Long noncoding RNAs and human disease. Trends Cell Biol. 21, 354–361 (2011).
Spizzo, R., Almeida, M. I., Colombatti, A. & Calin, G. A. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene 31, 4577–4587 (2012).
Schmitt, A. M. & Chang, H. Y. Long noncoding RNAs in cancer pathways. Cancer Cell 29, 452–463 (2016).
Huarte, M. The emerging role of lncRNAs in cancer. Nat. Med. 21, 1253–1261 (2015).
Chang, Y. N. et al. Hypoxia-regulated lncRNAs in cancer. Gene 575, 1–8 (2016).
Choudhry, H., Harris, A. L. & McIntyre, A. The tumour hypoxia induced non-coding transcriptome. Mol. Aspects Med. 47-48, 35–53 (2016).
Dong, J., Xu, J., Wang, X. & Jin, B. Influence of the interaction between long noncoding RNAs and hypoxia on tumorigenesis. Tumour Biol. 37, 1379–1385 (2016).
Augoff, K., McCue, B., Plow, E. F. & Sossey-Alaoui, K. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol. Cancer 11, 5 (2012).
Xi, S. et al. Cigarette smoke induces C/EBP-beta-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells. PLoS ONE 5, e13764 (2010).
Shi, Y. et al. Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells. Biochem. Biophys. Res. Commun. 446, 448–453 (2014).
Yang, H. et al. Long noncoding RNA MIR31HG exhibits oncogenic property in pancreatic ductal adenocarcinoma and is negatively regulated by miR-193b. Oncogene 35, 3647–3657 (2016).
Montes, M. et al. The lncRNA MIR31HG regulates p16(INK4A) expression to modulate senescence. Nat. Commun. 6, 6967 (2015).
Ding, J. et al. Long non-coding RNA Loc554202 induces apoptosis in colorectal cancer cells via the caspase cleavage cascades. J. Exp. Clin. Cancer Res. 34, 100 (2015).
Nie, F. Q. et al. Decreased long noncoding RNA MIR31HG is correlated with poor prognosis and contributes to cell proliferation in gastric cancer. Tumour Biol. 37, 7693–7701 (2016).
Ren, S. et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res. 22, 806–821 (2012).
Matouk, I. J. et al. The H19 non-coding RNA is essential for human tumour growth. PLoS ONE 2, e845 (2007).
Xue, M., Li, X., Li, Z. & Chen, W. Urothelial carcinoma associated 1 is a hypoxia-inducible factor-1alpha-targeted long noncoding RNA that enhances hypoxic bladder cancer cell proliferation, migration, and invasion. Tumour Biol. 35, 6901–6912 (2014).
Byrne, M. B., Leslie, M. T., Gaskins, H. R. & Kenis, P. J. Methods to study the tumour microenvironment under controlled oxygen conditions. Trends Biotechnol. 32, 556–563 (2014).
Peng, C. H. et al. A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. PLoS ONE 6, e23452 (2011).
He, H. et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA 102, 19075–19080 (2005).
Vasko, V. et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc. Natl Acad. Sci. USA 104, 2803–2808 (2007).
Zhao, H. et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol. Biol. Cell 15, 2523–2536 (2004).
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
Wu, M. H. et al. Galectin-1-mediated tumour invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons. Mol. Cancer Res. 7, 311–318 (2009).
Semenza, G. L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625–634 (2010).
Tsai, Y. P. & Wu, K. J. Hypoxia-regulated target genes implicated in tumour metastasis. J. Biomed. Sci. 19, 102 (2012).
Kuschel, A., Simon, P. & Tug, S. Functional regulation of HIF-1alpha under normoxia--is there more than post-translational regulation? J. Cell. Physiol. 227, 514–524 (2012).
Mills, C. N., Joshi, S. S. & Niles, R. M. Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions. Mol. Cancer 8, 104 (2009).
Arany, Z. et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl Acad. Sci. USA 93, 12969–12973 (1996).
Yu, T. M. et al. RANTES mediates kidney ischemia reperfusion injury through a possible role of HIF-1alpha and LncRNA PRINS. Sci. Rep. 6, 18424 (2016).
Gomez-Maldonado, L. et al. EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination. Oncogene 34, 2609–2620 (2015).
Wang, Y. et al. Hypoxia-inducible lncRNA-AK058003 promotes gastric cancer metastasis by targeting gamma-synuclein. Neoplasia 16, 1094–1106 (2014).
Yang, Z., Wang, R., Zhang, T. & Dong, X. Hypoxia/lncRNA-AK123072/EGFR pathway induced metastasis and invasion in gastric cancer. Int. J. Clin. Exp. Med. 8, 19954–19968 (2015).
Li, X. et al. Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway. Oncotarget 7, 6000–6014 (2016).
Yang, F., Zhang, H., Mei, Y. & Wu, M. Reciprocal regulation of HIF-1alpha and lincRNA-p21 modulates the Warburg effect. Mol. Cell 53, 88–100 (2014).
Choudhry, H. et al. Extensive regulation of the non-coding transcriptome by hypoxia: role of HIF in releasing paused RNApol2. EMBO Rep. 15, 70–76 (2014).
Zhou, C. et al. Long noncoding RNA HOTAIR, a hypoxia-inducible factor-1alpha activated driver of malignancy, enhances hypoxic cancer cell proliferation, migration, and invasion in non-small cell lung cancer. Tumour Biol. 36, 9179–9188 (2015).
Takahashi, K., Yan, I. K., Haga, H. & Patel, T. Modulation of hypoxia-signaling pathways by extracellular linc-RoR. J. Cell Sci. 127, 1585–1594 (2014).
Ferdin, J. et al. HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts. Cell Death Differ. 20, 1675–1687 (2013).
McCarty, G. & Loeb, D. M. Hypoxia-sensitive epigenetic regulation of an antisense-oriented lncRNA controls WT1 expression in myeloid leukemia cells. PLoS ONE 10, e0119837 (2015).
Thrash-Bingham, C. A. & Tartof, K. D. aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J. Natl Cancer Inst. 91, 143–151 (1999).
Yang, F. et al. Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol. Cell 49, 1083–1096 (2013).
Sun, Y. W. et al. A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1alpha in pancreatic ductal adenocarcinoma. Br. J. Cancer 111, 2131–2141 (2014).
Zhai, W. et al. Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2alpha/C-MYC axis under hypoxia. Oncogene 35, 4866–4880 (2016).
Wang, Y. et al. A novel long non-coding RNA, hypoxia-inducible factor-2alpha promoter upstream transcript, functions as an inhibitor of osteosarcoma stem cells in vitro. Mol. Med. Rep. 11, 2534–2540 (2015).
Lin, A. et al. The LINK-A lncRNA activates normoxic HIF1alpha signalling in triple-negative breast cancer. Nat. Cell Biol. 18, 213–224 (2016).
Feng, J. et al. The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator. Genes Dev. 20, 1470–1484 (2006).
Bond, A. M. et al. Balanced gene regulation by an embryonic brain ncRNA is critical for adult hippocampal GABA circuitry. Nat. Neurosci. 12, 1020–1027 (2009).
Holdt, L. M. et al. Alu elements in ANRIL non-coding RNA at chromosome 9p21 modulate atherogenic cell functions through trans-regulation of gene networks. PLoS Genet. 9, e1003588 (2013).
Melvin, A. & Rocha, S. Chromatin as an oxygen sensor and active player in the hypoxia response. Cell. Signal. 24, 35–43 (2012).
Wang, J. Q. & Wu, K. J. Epigenetic regulation of epithelial-mesenchymal transition by hypoxia in cancer: targets and therapy. Curr. Pharm. Des. 21, 1272–1278 (2015).
Veness, M. J., Morgan, G. J., Sathiyaseelan, Y. & Gebski, V. Anterior tongue cancer and the incidence of cervical lymph node metastases with increasing tumour thickness: should elective treatment to the neck be standard practice in all patients? ANZ J. Surg. 75, 101–105 (2005).
Ganly, I., Patel, S. & Shah, J. Early stage squamous cell cancer of the oral tongue--clinicopathologic features affecting outcome. Cancer 118, 101–111 (2012).
Cheng, L. et al. L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J. 30, 800–813 (2011).
Xie, H. et al. Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumour progression in mouse models of lung cancer and impacts tumour-initiating cells. Cell Metab. 19, 795–809 (2014).
Shibuya, K. et al. Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumour-initiating capacity of cancer stem cells. Oncotarget 6, 651–661 (2015).
Tan, J. et al. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumour-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov. 3, 1156–1171 (2013).
Semenza, G. L. Hypoxia-inducible factors in physiology and medicine. Cell 148, 399–408 (2012).
Onnis, B., Rapisarda, A. & Melillo, G. Development of HIF-1 inhibitors for cancer therapy. J. Cell. Mol. Med. 13, 2780–2786 (2009).
Hsiao, W. C., Sung, S. Y., Liao, C. H., Wu, H. C. & Hsieh, C. L. Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumour growth. Mol. Pharm. 9, 1396–1408 (2012).
Tsai, M. C. et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 329, 689–693 (2010).
Hung, C. L. et al. A long noncoding RNA connects c-Myc to tumour metabolism. Proc. Natl Acad. Sci. USA 111, 18697–18702 (2014).
Chu, C., Quinn, J. & Chang, H. Y. Chromatin isolation by RNA purification (ChIRP). J. Vis. Exp. 61, e3912 (2012).
We are sincerely grateful to the following individuals at PhD Program for Translational Medicine, Taipei Medical University: Dr Chia-Ling Hsieh for providing luciferase labelling lentiviral stock; Dr Hao-Ching Wang for providing protein expression vector; Po-Yang Huang, Ju-Hui Wu, Yu-Ju Chiu and Dr Yi-Pei Lin for their technical assistance. We thank Dr Pei-Ching Chang (Institute of Microbiology and Immunology, National Yang-Ming University) for help in the initial hypoxia screening. This work was supported by grants NSC101-2917-I-564-022, NSC102-2811-B-038-008 and NSC102-2321-B-038-006 (to J.W.S.) from National Science Council of Taiwan; CLFHR10422 and CLFHR10528 (to W.F.C.) from Chi-Mei Medical Center Liouying, Taiwan; MOHW106-TDU-B-212-144001 (to Y.Y.) from Health and welfare surcharge of tobacco products; CA114575 and CA165263 (to H.J.K.) from US National Institutes of Health; NHRI03A1-MGPP18-014, NHRI04A1-MGPP15-014 and NHRI05A1-MGPP15-014 (to H.J.K.) from National Health Research Institutes of Taiwan; MOHW104-TDU-M-212-13304 (to H.J.K.) from Ministry of Health and Welfare of Taiwan; MOST102-2320-B-400-018-MY3 and MOST104-2321-B-400-009 (to H.J.K.) from Ministry of Science and Technology of Taiwan.
The authors declare no competing financial interests.
About this article
EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway
Cancer Biology & Therapy (2019)
Depletion of PCAT-1 in head and neck cancer cells inhibits tumor growth and induces apoptosis by modulating c-Myc-AKT1-p38 MAPK signalling pathways
BMC Cancer (2019)
Systematic discovery of the functional impact of somatic genome alterations in individual tumors through tumor-specific causal inference
PLOS Computational Biology (2019)
Scientific Reports (2019)
Biomedicine & Pharmacotherapy (2019)